BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.

Authors :: Xuping Xie
Dormitzer, Philip R.
Pei-Yong Shi
Liu, Yang
Liu, Jianying
Xia, Hongjie
Zhang, Xianwen
Zou, Jing
Fontes-Garfias, Camila R
Weaver, Scott C
Swanson, Kena A
Cai, Hui
Sarkar, Ritu
Chen, Wei
Cutler, Mark
Cooper, David
Muik, Alexander
Sahin, Ugur
Jansen, Kathrin U
Xie, Xuping
Source :: New England Journal of Medicine. 7/29/2021, Vol. 385 Issue 5, p472-474. 3p.
Publication Year :: 2021
Abstract: The article focuses on BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. Topics include the variants that were first detected in California (B.1.429 lineage) and New York (B.1.526 lineage) are causing concern in the U.S., and the messenger RNA vaccine that expresses the prefusion stabilized full spike glycoprotein (S) of SARS-CoV-2 isolate Wuhan-Hu-1 is 95% effective against Covid-19.